Adjuvant therapy for melanoma.

PubWeight™: 1.01‹?› | Rank: Top 15%

🔗 View Article (PMC 3478763)

Published in Cancer J on March 28, 2012


Diwakar Davar1, Ahmad A Tarhini, John M Kirkwood

Author Affiliations

1: Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA.

Associated clinical trials:

Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma | NCT00679289

Articles citing this

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Induction of apoptosis by 11-dehydrosinulariolide via mitochondrial dysregulation and ER stress pathways in human melanoma cells. Mar Drugs (2012) 1.00

Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett (2012) 0.98

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncol (2015) 0.95

Proteomic investigation of the sinulariolide-treated melanoma cells A375: effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascade. Mar Drugs (2013) 0.85

Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol (2013) 0.82

Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach. Wien Med Wochenschr (2013) 0.81

Sinulariolide Suppresses Human Hepatocellular Carcinoma Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 through MAPKs and PI3K/Akt Signaling Pathways. Int J Mol Sci (2015) 0.79

BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog (2014) 0.79

Primary malignant melanoma of the breast: A case report and review of the literature. Oncol Lett (2014) 0.75

Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report. J Med Case Rep (2016) 0.75

Para-Phenylenediamine Induces Apoptotic Death of Melanoma Cells and Reduces Melanoma Tumour Growth in Mice. Biochem Res Int (2016) 0.75

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet (1998) 3.84

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol (2003) 3.13

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol (2009) 2.63

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol (2002) 2.57

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev (2003) 2.08

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet (2005) 1.60

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol (2002) 1.60

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res (2010) 1.54

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28

Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res (2007) 1.27

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol (2008) 1.19

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol (2010) 1.14

Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg (2002) 1.11

Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol (2002) 1.10

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol (1995) 1.05

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother (2004) 1.04

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol (2001) 1.04

Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol (2009) 1.01

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol (2010) 1.00

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol (2008) 0.99

Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med (1999) 0.97

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer (2004) 0.96

Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys (2006) 0.96

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer (2001) 0.93

Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci (2009) 0.92

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer (2004) 0.91

The expanding universe of regulatory T cell subsets in cancer. Immunity (2007) 0.88

Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ (2006) 0.84

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer (2012) 0.83

A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16. Cancer Immun (2003) 0.79

Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78

Articles by these authors

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64

Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer (2004) 3.46

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00

Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem (2004) 2.90

Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89

Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer (2009) 2.78

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65

Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26

An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2008) 2.09

Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05

The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00

Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90

Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77

IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76

Next generation of immunotherapy for melanoma. J Clin Oncol (2008) 1.69

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol (2007) 1.57

Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med (2010) 1.39

Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res (2007) 1.35

New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother (2008) 1.32

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31

Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol (2004) 1.30

Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol (2008) 1.25

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. Cancer Res (2013) 1.22

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J Clin Invest (2015) 1.22

Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg (2010) 1.20

Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol (2005) 1.19

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol (2008) 1.19

Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes. Cancer Biol Ther (2004) 1.16

Integrins and cancer. Oncology (Williston Park) (2007) 1.16

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol (2005) 1.15

Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res (2011) 1.13

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res (2002) 1.13

Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother (2012) 1.13

New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12

Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol (2003) 1.12

IFN-α in the treatment of melanoma. J Immunol (2012) 1.12

Management of metastatic melanoma. Semin Oncol (2007) 1.11

Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 1.11

Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer (2012) 1.10

Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med (2011) 1.10

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09

A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res (2013) 1.08

The accuracy of predicting survival in individual patients with cancer. J Neurosurg (2013) 1.08

Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer (2005) 1.08

Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res (2008) 1.08

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol (2002) 1.07

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer (2010) 1.06

Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol (2009) 1.05

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04

Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res (2011) 1.03

Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother (2007) 1.03

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer (2010) 1.02

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02

Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther (2010) 1.02

Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg (2006) 1.00

Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med (2012) 0.99

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med (2011) 0.99

Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol (2010) 0.98

Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. Arch Ophthalmol (2005) 0.97

Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice. J Virol Methods (2012) 0.96

Molecularly targeted therapy for melanoma: current reality and future options. Cancer (2006) 0.96

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res (2003) 0.96

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res (2008) 0.95

Mitochondrial respiration--an important therapeutic target in melanoma. PLoS One (2012) 0.95

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget (2014) 0.94

Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol (2011) 0.94

Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol (2006) 0.94